Wikipedia preview

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.(May 2015)(Learn how and when to remove this template message)

Graft (surgery)

Intervention

MeSH

D019737

[edit on Wikidata]

Grafting refers to a surgical procedure to move tissue from one site to another on the body, or from another person, without bringing its own blood supply with it. Instead, a new blood supply grows in after it is placed. A similar technique where tissue is transferred with the blood supply intact is called a flap. In some instances a graft can be an artificially manufactured device. Examples of this are a tube to carry blood flow across a defect or from an artery to a vein for use in hemodialysis.

Contents

1Classification

2Types of grafting

3Indications

4Reasons for failure

5References

Classification

Autografts and isografts are usually not considered as foreign and, therefore, do not elicit rejection. Allografts and xenografts are recognized as foreign by the recipient and are rejected.[1]

Autograft: graft taken from one part of the body of an individual and transplanted onto another site in the same individual, e.g., skin graft.

Isograft: graft taken from one individual and placed on another individual of the same genetic constitution, e.g., grafts between identical twins.

Allograft: graft taken from one individual placed on genetically non-identical member of the same species, e.g., the majority of grafts are allografts.

Xenograft: graft taken from one individual placed on an individual belonging to another species, e.g., animal to man.

Types of grafting

The term grafting is most commonly applied to skin grafting, however many tissues can be grafted: skin, bone, nerves, tendons, neurons, blood vessels, fat, and cornea are tissues commonly grafted today.

Specific types include:

Skin grafting is often used to treat skin loss due to a wound, burn, infection, or surgery. In the case of damaged skin, it is removed, and new skin is grafted in its place. Skin grafting can reduce the course of treatment and hospitalization needed, and can also improve function and appearance. There are two types of skin grafts:

英文文献

Ingels A1, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, Santos J, Peehl DM.Author information 1Department of Urology, Stanford University School of Medicine, Stanford, CA; Department of Urology, Centre Hospitalier Universitaire du Kremlin-Bicêtre, Kremlin-Bicêtre, France.AbstractmTOR is a rational target in renal cell carcinoma (RCC) because of its role in disease progression. However, the effects of temsirolimus, the only first-generation mTOR inhibitor approved by the FDA for first-line treatment of metastatic RCC, on tumor reduction and progression-free survival are minimal. Second-generation mTOR inhibitors have not been evaluated on RCC. We compared the effects of temsirolimus and MLN0128, a potent second-generation mTOR inhibitor, on RCC growth and metastasis using a realistic patient-derived tissue slice graft (TSG) model. TSGs were derived from three fresh primary RCC specimens by subrenal implantation of precision-cut tissue slices into immunodeficient mice that were randomized and treated with MLN0128, temsirolimus, or placebo. MLN0128 consistently suppressed primary RCC growth, monitored by magnetic resonance imaging (MRI), in three TSG cohorts for up to 2 months. Temsirolimus, in contrast, only transiently inhibited the growth of TSGs in one of two cohorts before resistance developed. In addition, MLN0128 reduced liver metastases, determined by human-specific quantitative polymerase chain reaction, in two TSG cohorts, whereas temsirolimus failed to have any significant impact. Moreover, MLN0128 decreased levels of key components of the two mTOR subpathways including TORC1 targets 4EBP1, p-S6K1, HIF1α and MTA1 and the TORC2 target c-Myc, consistent with dual inhibition. Our results demonstrated that MLN0128 is superior to temsirolimus in inhibiting primary RCC growth as well as metastases, lending strong support for further clinical development of dual mTOR inhibitors for RCC treatment.

mTOR is a rational target in renal cell carcinoma (RCC) because of its role in disease progression. However, the effects of temsirolimus, the only first-generation mTOR inhibitor approved by the FDA for first-line treatment of metastatic RCC, on tumor reduction and progression-free survival are mini

The development of effective therapeutic strategies against prostate cancer bone metastases has been impeded by the lack of adequate animal models that are able to recapitulate the biology of the disease in humans. Bioengineered approaches allow researchers to create sophisticated experimentally and

「an operation moving an organ from one organism (the donor) to another (the recipient); "he had a kidney transplant"; "the long-term results of cardiac transplantation are now excellent"; "a child had a multiple organ transplant two months ago"」

「the act of removing something from one location and introducing it in another location; "the transplant did not flower until the second year"; "too frequent transplanting is not good for families"; "she returned to Alabama because she could not bear transplantation"」